Physician profile
Andrew Kim
NPI 1316347537
$4,638.96
in general payments reported to CMS, 2019-2025
15 companies · $664 in 2025
The $664 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $791 · 2022: $880 · 2023: $411 · 2024: $1,893 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,967.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,540.02 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,021.77 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $556.14 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $401.88 | 2022-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $237.57 | 2024 | Xifaxan |
| Abbott Laboratories | $127.47 | 2022 | |
| Amgen INC. | $125.00 | 2021 | |
| Gilead Sciences, INC. | $124.94 | 2024 | Epclusa |
| Janssen Biotech, INC. | $123.36 | 2024 | Stelara, Tremfya |
| Genzyme Corporation | $107.62 | 2022 | |
| Abbvie INC. | $107.61 | 2023 | |
| Sunovion Pharmaceuticals INC. | $51.49 | 2021 | |
| Dexcom, INC. | $48.04 | 2023-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $44.25 | 2023-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Sumitomo Pharma America, INC. | $21.80 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.